NASDAQ:ONTX Onconova Therapeutics - ONTX Stock Forecast, Price & News Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat Daily Premium to add more stocks to your watchlist. Adding Onconova Therapeutics, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. $0.73 +0.01 (+1.39%) (As of 03/24/2023 12:00 AM ET) Add Compare Share Share Today's Range$0.69▼$0.7650-Day Range$0.69▼$1.4252-Week Range$0.62▼$2.04Volume41,684 shsAverage Volume78,108 shsMarket Capitalization$15.26 millionP/E RatioN/ADividend YieldN/APrice TargetN/A ProfileAnalyst RatingsChartCompetitorsEarningsFinancialsInsider TradesInstitutional OwnershipHeadlinesSEC FilingsShort InterestSocial Media About Onconova Therapeutics (NASDAQ:ONTX) StockOnconova Therapeutics, Inc. is a clinical-stage biopharmaceutical company, which engages in the identification and development of oncology therapeutics. It focuses on discovering and developing small molecule drug candidates to treat cancer. The company was founded by Ramesh Kumar and E. Premkumar Reddy on December 22, 1998 and is headquartered in Newtown, PA.Read More Receive ONTX Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Onconova Therapeutics and its competitors with MarketBeat's FREE daily newsletter. Email Address ONTX Stock News HeadlinesMarch 23, 2023 | markets.businessinsider.comOnconova Therapeutics (ONTX) Gets a Hold from H.C. WainwrightMarch 23, 2023 | finance.yahoo.comOnconova Therapeutics and Pangea Biomed Enter into Research Collaboration to Identify Biomarkers of Response to RigosertibMarch 26, 2023 | Stansberry Research (Ad)The gold catalyst we’ve waited forIf you thought the SVB meltdown was bad… watch out. Because even bigger red flag just appeared. This signal proves that a recession is likely right around the corner. It will take most by surprise. Stocks will crash. Millions will go jobless, and lose their homes. But there is ONE important step you should take today to make sure you come out the other side OK. March 21, 2023 | americanbankingnews.comOnconova Therapeutics, Inc. (NASDAQ:ONTX) Expected to Post Q1 2023 Earnings of ($0.27) Per ShareMarch 20, 2023 | americanbankingnews.comOnconova Therapeutics (NASDAQ:ONTX) Now Covered by StockNews.comMarch 18, 2023 | finance.yahoo.comOnconova Therapeutics, Inc. (NASDAQ:ONTX) Q4 2022 Earnings Call TranscriptMarch 17, 2023 | markets.businessinsider.comH.C. Wainwright Sticks to Its Hold Rating for Onconova Therapeutics (ONTX)March 17, 2023 | finance.yahoo.comQ4 2022 Onconova Therapeutics Inc Earnings CallMarch 26, 2023 | Oxford Club (Ad)My No. 1 dividend stock for a LIFETIME of income.Few people realize this… But dividends account for up to 90% of the stock market's returns over the past century! I think it's a crying shame folks don't know how powerful dividends are.March 16, 2023 | msn.comOnconova Therapeutics GAAP EPS of -$0.91 misses by $0.63, revenue of $0.23M beats by $0.17MMarch 16, 2023 | finance.yahoo.comOnconova Therapeutics Reports Full Year 2022 Financial Results and Provides Business UpdateMarch 16, 2023 | markets.businessinsider.comAnalysts Offer Insights on Healthcare Companies: Onconova Therapeutics (ONTX) and Agilon Health (AGL)March 15, 2023 | msn.comPreview: Onconova Therapeutics's EarningsMarch 15, 2023 | finance.yahoo.comOnconova Therapeutics Announces Upcoming Poster Presentations at the AACR Annual MeetingMarch 9, 2023 | finance.yahoo.comOnconova Therapeutics to Provide Corporate Update and Announce Fourth Quarter and Full Year 2022 Financial Results on March 16, 2023March 7, 2023 | finance.yahoo.comOnconova Therapeutics Presents Preclinical Data Characterizing Rigosertib’s Mechanisms of Action at the AACR Targeting RAS ConferenceFebruary 7, 2023 | finance.yahoo.comOnconova Therapeutics Touts Additional Positive Data For Rigosertib Monotherapy In Skin Cancer SettingFebruary 7, 2023 | marketwatch.comOnconova Therapeutics Gets Positive Data for Rigosertib Trial ParticipantFebruary 7, 2023 | finance.yahoo.comOnconova Therapeutics Announces Additional Clinical Data Demonstrating Rigosertib’s Monotherapy Activity in RDEB-Associated Squamous Cell CarcinomaFebruary 6, 2023 | finance.yahoo.comWe Think Onconova Therapeutics (NASDAQ:ONTX) Needs To Drive Business Growth CarefullyFebruary 1, 2023 | finance.yahoo.comOnconova Therapeutics to Present at the 2023 Guggenheim Oncology ConferenceJanuary 26, 2023 | finance.yahoo.comOnconova Therapeutics Announces Participation in the Channelchek Takeaway SeriesJanuary 18, 2023 | reuters.comONTX.O - | Stock Price & Latest News | ReutersDecember 19, 2022 | finance.yahoo.comOnconova Therapeutics Appoints Drs. Peter Atadja and Trafford Clarke to its Board of DirectorsDecember 7, 2022 | finance.yahoo.comOnconova Therapeutics to Present at the Upcoming MedInvest Oncology Investor ConferenceNovember 28, 2022 | finance.yahoo.comOnconova Therapeutics to Present at the Upcoming RHK Capital Disruptive Growth ConferenceNovember 17, 2022 | finance.yahoo.comOnconova Therapeutics Third Quarter 2022 Earnings: Misses ExpectationsSee More Headlines View Price History Chart DataSkip Price History Chart 30 days | 90 days | 365 days | Advanced Chart Receive ONTX Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Onconova Therapeutics and its competitors with MarketBeat's FREE daily newsletter. Email Address ONTX Company Calendar Last Earnings11/11/2021Today3/26/2023Next Earnings (Estimated)5/10/2023Fiscal Year End12/31/2023Get Stock AlertsIndustry, Sector and Symbol Stock ExchangeNASDAQ Industry Pharmaceutical preparations Sub-IndustryN/A SectorMedical Current SymbolNASDAQ:ONTX CUSIPN/A CIK1130598 Webwww.onconova.com Phone(267) 759-3680Fax267-759-3681Employees14Year FoundedN/AProfitability EPS (Most Recent Fiscal Year)($0.91) Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet Income$-18,960,000.00 Net Margins-8,391.15% Pretax Margin-7,658.41% Return on Equity-49.84% Return on Assets-39.71% Debt Debt-to-Equity RatioN/A Current Ratio5.96 Quick Ratio5.96 Sales & Book Value Annual Sales$230,000.00 Price / Sales66.33 Cash FlowN/A Price / Cash FlowN/A Book Value$2.22 per share Price / Book0.33Miscellaneous Outstanding Shares20,900,000Free Float20,645,000Market Cap$15.26 million OptionableNot Optionable Beta1.84 Key ExecutivesSteven M. FruchtmanPresident, Chief Executive Officer & DirectorMark P. GuerinChief Operating & Financial OfficerMatthew ParrisVice President-Clinical OperationsMark Stephen GelderChief Medical OfficerAdar Makovski SilversteinSenior Director & Head-Corporate DevelopmentKey CompetitorsCocrystal PharmaNASDAQ:COCPRegulus TherapeuticsNASDAQ:RGLSCNS PharmaceuticalsNASDAQ:CNSPNanoViricidesNYSE:NNVCLexaria BioscienceNASDAQ:LEXXView All CompetitorsInstitutional OwnershipRenaissance Technologies LLCSold 37,448 shares on 2/13/2023Ownership: 0.802%Simplex Trading LLCBought 100 shares on 2/2/2023Ownership: 0.000%View All Institutional Transactions ONTX Stock - Frequently Asked Questions Should I buy or sell Onconova Therapeutics stock right now? 1 Wall Street research analysts have issued "buy," "hold," and "sell" ratings for Onconova Therapeutics in the last twelve months. There are currently 1 buy rating for the stock. The consensus among Wall Street research analysts is that investors should "buy" ONTX shares. View ONTX analyst ratings or view top-rated stocks. How have ONTX shares performed in 2023? Onconova Therapeutics' stock was trading at $0.6457 at the beginning of 2023. Since then, ONTX shares have increased by 13.1% and is now trading at $0.73. View the best growth stocks for 2023 here. When is Onconova Therapeutics' next earnings date? The company is scheduled to release its next quarterly earnings announcement on Wednesday, May 10th 2023. View our ONTX earnings forecast. How were Onconova Therapeutics' earnings last quarter? Onconova Therapeutics, Inc. (NASDAQ:ONTX) issued its quarterly earnings data on Thursday, November, 11th. The biopharmaceutical company reported ($0.22) EPS for the quarter, beating analysts' consensus estimates of ($0.33) by $0.11. The biopharmaceutical company earned $0.06 million during the quarter, compared to the consensus estimate of $0.06 million. Onconova Therapeutics had a negative trailing twelve-month return on equity of 49.84% and a negative net margin of 8,391.15%. During the same period in the prior year, the business earned ($0.45) EPS. When did Onconova Therapeutics' stock split? Onconova Therapeutics's stock reverse split on the morning of Friday, May 21st 2021. The 1-15 reverse split was announced on Thursday, May 20th 2021. The number of shares owned by shareholders was adjusted after the closing bell on Thursday, May 20th 2021. An investor that had 100 shares of stock prior to the reverse split would have 7 shares after the split. What other stocks do shareholders of Onconova Therapeutics own? Based on aggregate information from My MarketBeat watchlists, some companies that other Onconova Therapeutics investors own include Sorrento Therapeutics (SRNE), OPKO Health (OPK), SCYNEXIS (SCYX), VBI Vaccines (VBIV), Tonix Pharmaceuticals (TNXP), Acasti Pharma (ACST), Bionano Genomics (BNGO), Matinas BioPharma (MTNB), Outlook Therapeutics (OTLK) and Actinium Pharmaceuticals (ATNM). What is Onconova Therapeutics' stock symbol? Onconova Therapeutics trades on the NASDAQ under the ticker symbol "ONTX." Who are Onconova Therapeutics' major shareholders? Onconova Therapeutics' stock is owned by a variety of institutional and retail investors. Top institutional shareholders include Renaissance Technologies LLC (0.80%), Simplex Trading LLC (0.00%) and Concourse Financial Group Securities Inc. (0.00%). Insiders that own company stock include Abraham N Oler, Abraham N Oler, E Premkumar Reddy, James J Marino, Jerome Groopman, Mark Patrick Guerin and Steven M Fruchtman. View institutional ownership trends. How do I buy shares of Onconova Therapeutics? Shares of ONTX stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab. Compare Top Brokerages Here. What is Onconova Therapeutics' stock price today? One share of ONTX stock can currently be purchased for approximately $0.73. How much money does Onconova Therapeutics make? Onconova Therapeutics (NASDAQ:ONTX) has a market capitalization of $15.26 million and generates $230,000.00 in revenue each year. The biopharmaceutical company earns $-18,960,000.00 in net income (profit) each year or ($0.91) on an earnings per share basis. How can I contact Onconova Therapeutics? Onconova Therapeutics' mailing address is 375 PHEASANT RUN, NEWTOWN PA, 18940. The official website for the company is www.onconova.com. The biopharmaceutical company can be reached via phone at (267) 759-3680, via email at ir@onconova.us, or via fax at 267-759-3681. This page (NASDAQ:ONTX) was last updated on 3/26/2023 by MarketBeat.com Staff Get 30 Days of MarketBeat All Access Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools: Best-in-Class Portfolio Monitoring View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio. Stock Ideas and Recommendations Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report. Advanced Stock Screeners and Research Tools Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis. Start Your 30-Day Free Trial Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Your Password: or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Choose a Password: Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.